The Lipid Vector Technology (LVT) is a unique proprietary technology platform that enables Aqualis to create New Chemical Entities (NCEs) by significantly improving already well-established drugs. These new NCEs may offer improved efficacy and reduced side effects.
Some of the potential benefits of these LVT products are:
- Bypassing drug resistance
- Improved efficacy
- Personalised medicine through biomarker driven patient selection
- Prolonged effect and improved safety profile
Nucleoside drugs depend on nucleoside transporters to enter cancer cells where they exert their cytotoxic effect by inhibiting DNA synthesis and preventing cancer cell division and proliferation. Aqualis is investigating the potential of these transporters to be biomarkers for the development of companion diagnostics that will help select patients who might benefit from treatment with an LVT drug.
Unique LVT technology platform
Lipid Vector Technology involves chemically linking a specific lipid (vector) to a selected pharmaceutical agent (parent drug). The new molecule thus created is a New Chemical Entity (NCE) that can be patented. A large number of the Company’s NCEs covering a wide range of therapeutic areas have in model systems demonstrated enhanced biological performance compared to the parent drug. Clavis Pharma has shown that a variety of drug characteristics can be improved by linking fatty lipids to a drug.